Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
L'action Lonza en repli après la nomination d'un nouveau patron | Zone bourse
08:14am, Friday, 05'th Jun 2020Hedge Funds Souring On Incyte Corporation (INCY)
02:24am, Friday, 05'th Jun 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
Why Is Incyte (INCY) Up 2.9% Since Last Earnings Report?
03:31pm, Thursday, 04'th Jun 2020
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Incyte (INCY) Up 2.9% Since Last Earnings Report?
11:31am, Thursday, 04'th Jun 2020
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Zoom Video Communications : Distance et effet de loupe
05:04pm, Wednesday, 03'rd Jun 2020
Zoom entretient la flamme de Wall Street pour sa valorisation stratosphérique.
Incyte to Present at Upcoming Investor Conferences
12:00pm, Wednesday, 03'rd Jun 2020
Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June:
Eli Lilly (LLY) appears to be on a strong footing with COVID-19 drug development efforts | AlphaStreet
07:29pm, Tuesday, 02'nd Jun 2020
Eli Lilly & Co.'s (NYSE: LLY) shares have gained 29% since the beginning of the year and 16% over the past three months.
These 4 Biotech Stocks Are Outperforming Their Peers — Here's Why
02:00pm, Tuesday, 02'nd Jun 2020
The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.
New Research Points to Treatment for COVID-19 Cytokine Storms, Solution to Global Pandemic
12:02pm, Sunday, 31'st May 2020
How mice that model immune disease's cytokine storms may point to solution for global pandemic. A transgenic mouse developed at Cincinnati Children's to model the deadly childhood immune disease HLH (
Incyte (Nasdaq: INCY) gab heute bekannt, dass Daten aus der Zwischenanalyse der Phase-II-Studie OPTIC (Optimizing Ponatinib Treatment In CML), die von
Incyte To Highlight Data From Interim Analysis Of Phase 2 OPTIC Trial At ASCO
12:16pm, Friday, 29'th May 2020
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Trea
